SCHEMBL80822

SCHEMBL80822

Fc1ccc(Cl)cc1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121913 0.81
SCHEMBL30792966 0.79 TP53 (0.36)
SCHEMBL79921 0.74
SCHEMBL29720648 0.74
SCHEMBL29839691 0.74
SCHEMBL3880085 0.74
SCHEMBL959207 0.74
SCHEMBL29443091 0.73
SCHEMBL530450 0.73
SCHEMBL17135281 0.72 CES2 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114591290-A Preparation method of substituted benzo [ B ] naphthalene benzene [2, 3-D ] thiophene derivative and derivative 陕西维世诺新材料有限公司 2022-06-07 CN claimed
US-4870218-A Trihalobenzene compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-09-26 US claimed
EP-0252592-A1 Halogenated diphenyl ether derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-01-13 EP claimed
EP-4685143-A1 DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF Vivozon,Inc. (KR) 2026-01-28 EP disclosed
EP-4638438-A1 ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF Xinthera, Inc. (US) 2025-10-29 EP disclosed
CN-119176772-A Compound with Mrgpr X receptor inhibition effect and application thereof 博济医药科技股份有限公司 2024-12-24 CN disclosed
CN-118693282-B Secondary battery and preparation method and application thereof 蜂巢能源科技股份有限公司 2024-12-03 CN disclosed
WO-2024196136-A1 DOUBLE REGULATOR FOR MGLUR5 AND HDAC6 AND USE THEREOF 주식회사 비보존 2024-09-26 WO disclosed
CN-118693282-A Secondary battery and preparation method and application thereof 蜂巢能源科技股份有限公司 2024-09-24 CN disclosed
US-20240299385-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS REWIND THERAPEUTICS NV (BE) 2024-09-12 US disclosed
US-20240279214-A1 ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF XINTHERA, INC. 2024-08-22 US disclosed
WO-2012143725-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2012-10-26 WO disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
US-7732463-B2 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors H. LUNDBECK A/S (DK) 2010-06-08 US disclosed
EP-2168944-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
CN-1780622-A 4-(2-phenylsulfanyl-phenyl)-piperidine derivates as serotonin reuptake inhibitors LUNDBECK & CO AS H (DK) 2006-05-31 CN disclosed
US-20060100242-A1 such as 4-[2-(4-Chloro-phenylsulfanyl)-5-trifluoromethyl-phenyl]-piperidine, used as antidepressants and anxiolytic agents; treatment of panic and obsessive compulsive disorders H.LUNDBECK A/S (DK) 2006-05-11 US disclosed
EP-1626720-A1 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS H. Lundbeck A/S (DK) 2006-02-22 EP disclosed
WO-2004087156-A1 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS H. LUNDBECK A/S (DK) 2004-10-14 WO disclosed